MENU
+Compare
NAMS
Stock ticker: NASDAQ
AS OF
Sep 24, 04:59 PM (EDT)
Price
$26.73
Change
+$0.06 (+0.22%)
Capitalization
3B

NAMS NewAmsterdam Pharma Company NV Forecast, Technical & Fundamental Analysis

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated... Show more

NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NAMS with price predictions
Sep 23, 2025

NAMS in -9.32% downward trend, sliding for three consecutive days on September 15, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NAMS declined for three days, in of 174 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NAMS moved out of overbought territory on September 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

NAMS broke above its upper Bollinger Band on September 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 22, 2025. You may want to consider a long position or call options on NAMS as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on September 22, 2025. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 129 cases where NAMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NAMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.858) is normal, around the industry mean (19.924). P/E Ratio (0.000) is within average values for comparable stocks, (54.318). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.126). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (44.643) is also within normal values, averaging (347.892).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NAMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NAMS is expected to report earnings to rise 168.87% to -40 cents per share on November 17

NewAmsterdam Pharma Company NV NAMS Stock Earnings Reports
Q3'25
Est.
$-0.40
Q2'25
Beat
by $0.34
Q1'25
Beat
by $0.16
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.32
The last earnings report on August 06 showed earnings per share of -15 cents, beating the estimate of -49 cents. With 335.69K shares outstanding, the current market capitalization sits at 3.00B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Gooimeer 2-35
Phone
+31 352062971
Employees
29
Web
https://www.newamsterdampharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMVOX29.600.03
+0.10%
Lord Abbett Focused Small Cap Value F3
TRIEX28.28-0.05
-0.18%
Nuveen International Eq Idx Retire
PALRX19.18-0.05
-0.26%
PGIM Balanced R
BEGRX18.48-0.05
-0.27%
Franklin Mutual Beacon Z
DFMLX39.12-0.25
-0.64%
DF Dent Midcap Growth Institutional Plus

NAMS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with QURE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-1.40%
QURE - NAMS
56%
Loosely correlated
-1.23%
CRDF - NAMS
41%
Loosely correlated
-1.45%
BEAM - NAMS
39%
Loosely correlated
-2.79%
OCUL - NAMS
38%
Loosely correlated
+0.41%
XNCR - NAMS
37%
Loosely correlated
-0.67%
More